• FirefoxUpgrade to the new Firefox »
  •  Dow Down0.79% Nasdaq Up0.16%

    Bristol-Myers Squibb Company (BMY)

    -NYSE
    62.07 Down 0.02(0.03%) Jan 23, 4:04PM EST
    |After Hours : 62.29 Up 0.22 (0.35%) Jan 23, 4:56PM EST
    Add to Portfolio
    ProfileGet Profile for:
    Bristol-Myers Squibb Company
    345 Park Avenue
    New York, NY 10154
    United States - Map
    Phone: 212-546-4000
    Fax: 212-546-4020
    Website: http://www.bms.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Drug Manufacturers - Major
    Full Time Employees:28,000

    Business Summary 

    Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It provides chemically-synthesized drugs or small molecule products, and biologics in various therapeutic areas, including virology comprising human immunodeficiency virus infection (HIV); oncology; neuroscience; metabolics; immunoscience; and cardiovascular. The company’s principal products are virology products comprising Baraclude, Reyataz, and Sustiva; oncology products, including Erbitux, Sprycel, and Yervoy; neuroscience products, such as Abilify; metabolics consisting of Bydureon, Byetta, Forxiga, and Onglyza/Kombiglyze; immunoscience products, including Nulojix and Orencia; and cardiovascular products, such as Avapro/Avalide, Eliquis, and Plavix. It has various products under Phase III clinical trials for the treatment of hepatitis C virus infection, including Asunaprevir; Daclatasvir; BMS-791325; and Peginterferon lambda. The company also has various products under Phase III clinical trials for treatment of cancer comprising Elotuzumab and Nivolumab. In addition, it develops Baraclude and Reyataz for pediatric extensions; Erbitux for esophageal cancer; Yervoy for melanoma, prostate cancer, and non-small-cell and small cell lung cancer; Orencia for lupus nephritis and psoriatic arthritis; and Eliquis for venous thromboembolic treatment and prevention. The company sells its products to wholesalers, and directly to distributors, retailers, hospitals, clinics, government agencies, and pharmacies. It has strategic alliance with OliPass Corporation to discover and develop therapeutics against various targets using OliPass' technology platform. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Bristol-Myers Squibb Company

    Corporate Governance 
    Bristol-Myers Squibb Company’s ISS Governance QuickScore as of Jan 1, 2015 is 5. The pillar scores are Audit: 10; Board: 6; Shareholder Rights: 5; Compensation: 5.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
     PayExercised
    Mr. Lamberto Andreotti , 64
    Chief Exec. Officer, Director, Member of Exec. Committee and Member of Securities Issuance Committee
    6.26M0.00
    Mr. Charles A. Bancroft , 55
    Chief Financial Officer and Exec. VP
    2.34M0.00
    Mr. Giovanni Caforio M.D., 50
    Chief Operating Officer and Director
    1.71M613.00K
    Dr. Francis M. Cuss MB BChir, FRCP, 60
    Chief Scientific Officer, Exec. VP and Member of Science & Technology Committee
    1.64M1.25M
    Ms. Sandra Leung , 54
    Gen. Counsel and Corp. Sec.
    1.93M265.00K
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders